Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Alan Campbell is active.

Publication


Featured researches published by David Alan Campbell.


Current Opinion in Chemical Biology | 2003

Functional profiling of the proteome with affinity labels

David Alan Campbell; Anna Katrin Szardenings

The analysis of proteomic samples with affinity labels has been firmly established as a tool for the post-genomic researcher. Recent examples highlight the advantages of profiling functionally active members of specific protein families to identify therapeutically relevant protein targets that have escaped normal physiological regulation leading to increased or decreased activity. This dysregulation may result from any number of biological changes that modulate a proteins activity; for example, post-translational modifications of the protein or an imbalance between the protein and its endogenous inhibitor(s). By providing a direct measure of a proteins functional activity, affinity probe analysis identifies these changes and allows investigators to focus their research efforts upon those proteins that are most likely to be responsible for the biological changes under evaluation.


Bioorganic & Medicinal Chemistry Letters | 2009

Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.

Amogh Boloor; Denise Hanway; Maria Joshi; David T. Winn; Gabriel Mendez; Marlena Walls; Ping Wei; Fuxin Qian; Xiaoli Zhang; Yuliang Zhang; Michael Hepperle; Xinqiang Li; David Alan Campbell; Juan Manuel Betancort

A new series of NS3/4A protease boronic acid inhibitors is described. The compounds show good biochemical potency and cellular activity. The peptidomimetic inhibitors were evaluated against proteases from different HCV genotypes and clinically relevant NS3/4A mutants. Compound 28 displayed subnanomolar to single digit nanomolar potencies in the enzymatic assays and an EC50 of 25 nM in the replicon cell-based assay.


Bioorganic & Medicinal Chemistry Letters | 1998

Malonyl α-mercaptoketones and α-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors

David Alan Campbell; Xiao-Yi Xiao; David Harris; Satoru Ida; Reza Mortezaei; Khehyong Ngu; Lihong Shi; David Tien; Yongwen Wang; Marc Navre; Dinesh V. Patel; Michele A. Sharr; John F. DiJoseph; Loran M. Killar; Christina Louise Leone; Jeremy I. Levin; Jerauld S. Skotnicki

Abstract A novel series of matrix metalloproteinase (MMP) inhibitors is described. Incorporation of a terminal α-mercaptoketone or α-mercaptoalcohol in the zinc binding domain of a series of inhibitors led to compounds exhibiting low nanomolar activity against collagenase-1 (MMP-1), stromelysin (MMP-3), and gelatinase-B (MMP-9).


Bioorganic & Medicinal Chemistry Letters | 2009

Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.

Juan Manuel Betancort; David T. Winn; Ruzhang Liu; Quansheng Xu; Junjuan Liu; Wensheng Liao; Shuhui Chen; David Carney; Denise Hanway; James Schmeits; Xinqiang Li; Eric M. Gordon; David Alan Campbell

The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species. The inhibitors show good to moderate biochemical potency against DPP4 and display distinct selectivity profiles towards DPP7, DPP8 and DPP9 depending on their substitution.


Molecular Diversity | 1998

Preparation of N-alkylated 5-oxo-3-carboxamyl-1,4-thiazinanes on solid support

Reza Mortezaei; Satoru Ida; David Alan Campbell

A general method was developed to generate six-membered cyclic thiazinanes on solid support. Three diversity sites were introduced into this scaffold using primary amines, aldehydes, and 2-bromoalkanoic acids. The methodology to prepare individual cyclic thiazinanes as well as combinatorial libraries of these compounds is described.


Archive | 2004

Heterocyclic boronic acid compounds

David Alan Campbell; David T. Winn; Juan Manuel Betancort


Archive | 1996

Method for synthesis of diketopiperazine and diketomorpholine derivatives

Anna Katrin Szardenings; David Alan Campbell


Journal of Medicinal Chemistry | 1999

Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.

Anna Katrin Szardenings; Valery V. Antonenko; David Alan Campbell; Nuria DeFrancisco; Satoru Ida; Lihong Shi; Nikolai Sharkov; David Tien; Yongwen Wang; Marc Navre


Antimicrobial Agents and Chemotherapy | 1998

Screening for Novel Antimicrobials from Encoded Combinatorial Libraries by Using a Two-Dimensional Agar Format

Joy L. Silen; Amy T. Lu; Dennis W. Solas; Medini A. Gore; Derek Maclean; Nikil H. Shah; Jill M. Coffin; Naseema S. Bhinderwala; Yongwen Wang; Ken Tsutsui; Gary C. Look; David Alan Campbell; Ron L. Hale; Marc Navre; Camille R. DeLuca-Flaherty


Journal of Medicinal Chemistry | 1998

Rational design and combinatorial evaluation of enzyme inhibitor scaffolds : Identification of novel inhibitors of matrix metalloproteinases

Anna Katrin Szardenings; David Harris; Stuart Lam; Lihong Shi; David Tien; Yongwen Wang; Dinesh V. Patel; Marc Navre; David Alan Campbell

Collaboration


Dive into the David Alan Campbell's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gary C. Look

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Satoru Ida

Santa Clara University

View shared research outputs
Top Co-Authors

Avatar

Marc Navre

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Lihong Shi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

David Harris

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Eric M. Gordon

University of Wisconsin-Madison

View shared research outputs
Researchain Logo
Decentralizing Knowledge